In the last trading session, 1.81 million Relmada Therapeutics Inc (NASDAQ:RLMD) shares changed hands as the company’s beta touched -0.26. With the company’s per share price at $0.65 changed hands at -$0.09 or -12.51% during last session, the market valuation stood at $21.41M. RLMD’s last price was a discount, traded about -587.69% off its 52-week high of $4.47. The share price had its 52-week low at $0.24, which suggests the last value was 63.08% up since then. When we look at Relmada Therapeutics Inc’s average trading volume, we note the 10-day average is 5.88 million shares, with the 3-month average coming to 1.79 million.
Analysts gave the Relmada Therapeutics Inc (RLMD) stock a consensus recommendation rating of Sell, calculated at a mean rating of 3.00. If we narrow down to specifics, the data shows that 1 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended RLMD as a Hold, 0 felt it is a Buy and 0 rated the stock as Underweight. Relmada Therapeutics Inc’s EPS for the current quarter is expected to be 0.
Relmada Therapeutics Inc (NASDAQ:RLMD) trade information
Instantly RLMD was in red as seen at the end of in last trading. With action 122.60%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 24.06%, with the 5-day performance at 122.60% in the green. However, in the 30-day time frame, Relmada Therapeutics Inc (NASDAQ:RLMD) is 110.20% up. Looking at the short shares, we see there were 1.41 million shares sold at short interest cover period of 4.03 days.
The consensus price target for the stock as assigned by Wall Street analysts is 7, meaning bulls need an upside of 90.71% from its current market value. According to analyst projections, RLMD’s forecast low is 2 with 8 as the target high. To hit the forecast high, the stock’s price needs a -1130.77% plunge from its current level, while the stock would need to soar -207.69% for it to hit the projected low.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 0.68%. The 2025 estimates are for Relmada Therapeutics Inc earnings to increase by 34.72%, but the outlook for the next 5-year period is at 19.94% per year.
RLMD Dividends
Relmada Therapeutics Inc is expected to release its next quarterly earnings report on 2025-Mar-26.
Relmada Therapeutics Inc (NASDAQ:RLMD)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 17.03% of Relmada Therapeutics Inc shares while 33.96% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 40.93%. There are 33.96% institutions holding the Relmada Therapeutics Inc stock share, with VANGUARD GROUP INC the top institutional holder. As of 2024-06-30, the company held 16.6593% of the shares, roughly 1.26 million RLMD shares worth $3.77 million.
DEEP TRACK CAPITAL, LP holds the second largest percentage of outstanding shares, with 16.3686% or 1.23 million shares worth $3.7 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Franklin Strategic Series-FRANKLIN BIOTECHNOLOGY DISCOVERY FUND . With 851.92 shares estimated at $0.55 million under it, the former controlled 8.61% of total outstanding shares. On the other hand, Franklin Strategic Series-FRANKLIN BIOTECHNOLOGY DISCOVERY FUND held about 4.61% of the shares, roughly 456.4 shares worth around $0.29 million.
